<DOC>
	<DOCNO>NCT02297477</DOCNO>
	<brief_summary>This two-arm , randomize , open label Treatment Study evaluate therapeutic efficacy , safety , tolerability pharmacokinetics three-day course Atovaquone-Proguanil ( AP ) three-day course Atovaquone-Proguanil combine 3 day Artesunate ( ASAP ) patient uncomplicated Plasmodium falciparum malaria select site Cambodia . Atovaquone-proguanil , soon adopt first line antimalarial agent National Malaria Control Program ( CNM ) Cambodia province confirm multidrug resistance , give without artesunate ( AS ) directly observe , standard three-day fix dose combination treatment volunteer enrol . The efficacy safety drug combination well evidence vivo vitro resistance component monitor treatment period . All volunteer receive single dose 15mg primaquine recommend WHO first dose AP ASAP block transmission malaria mosquito . Resistance AP ASAP assess combination clinical , pharmacologic , parasitological parameter include genomic signature selection careful weekly follow-up visit 6 week . Investigators also able evaluate effect primaquine sexual stage malaria ( gametocyte ) .</brief_summary>
	<brief_title>The ASAP Study - Therapeutic Efficacy Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil Cambodia</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Atovaquone , proguanil drug combination</mesh_term>
	<criteria>1 . Male female uncomplicated P. falciparum malaria ( volunteer mix P. falciparum P. vivax infection may enrol ) , 1865 year age 2 . Baseline asexual parasite density 100200,000 parasites/microL 3 . Able provide inform consent 4 . Available agree followup anticipate study duration include 3 day treatment course Medical Treatment Facility , weekly followup 42day period . 1 . Allergic reaction medical contraindication atovaquone , proguanil , artesunate primaquine , include calculate serum creatinine clearance estimate le 30mL/min 2 . Significant acute comorbidity require urgent medical intervention 3 . Signs/symptoms parasitological confirmation severe malaria 4 . Use antimalarial within past 7 day , atovaquoneproguanil past 30 day 5 . Use follow concomitant medication within 7 day , may cause volunteer significant drugdrug interaction study drug tetracycline , metoclopramide , rifampin , rifabutin , zidovudine etoposide . 6 . Pregnant lactate female , female childbearing age , 50 year age , agree use acceptable form contraception study 7 . Judged investigator otherwise unsuitable study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>